Month: February 2024

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) — Imperial Metals Corporation (“Imperial”) (TSX:III) reports that Newmont Corporation (Newmont) has updated its mineral reserves and resources estimates for the Red Chris project. The Newmont mineral reserve and resource statement for Red Chris mine will be reported in line with SEC mining reporting standards, rather than National Instrument 43-101 (“NI 43-101”) standards, due to Newmont’s primary listing as a US-listed issuer. Newmont used the previous Newcrest mineral reserve and resource estimates as a base to which they applied both their internal standards and guidelines and the US SEC S-K 1300 reporting rules to prepare the updated reserve and resource statement. Whereas Newmont did not prepare an NI 43-101 report in the process of updating its mineral reserve and...

SKEL fjárfestingafélag hf.’s Annual General Meeting will be held on Thursday 7 March 2024 at 4:00 pm in the Ballroom at the Reykjavík Edition, Austurbakki 2, 101 Reykjavík. Enclosed is the final agenda and final proposals for the AGM 2024. No substantial changes have been made to the proposals or the agenda of the AGM since the meeting was convened on 15 February, except that the board proposes that the dividend payment date be April 16 instead of April 11. Deadline for shareholders to request item to be put on the agenda and to submit a proposal, such claim must be received before 4:00 pm on February 26.  Information on key dates and deadlines as well as documents for the AGM can be found on the company´s website: https://skel.is/en/shareholders/shareholder-meetings For further information please contact Ásgeir Helgi Reykfjörð Gylfason,...

Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signals Encouraging early results from the VAXINIA (CF33) oncolytic virus trial, including one complete response in a patient with cholangiocarcinoma (bile tract cancer) and two partial responses in patients with melanoma; two out of three of the responses were achieved with monotherapy CF33; receipt of US FDA Fast Track Designation for bile duct cancer Potential near-term registrational study and fast-to-market strategy for azer-cel allogeneic CAR T therapy in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) who progressed after autologous CAR T therapies World-first onCARlytics trial designed to convert “targetless” tumors to CD19-expressing solid tumors that are otherwise hard to treat; trial combines...

MONTRÉAL, Feb. 22, 2024 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (CSE: CDPR) (OTCPK: GPPRF) (FRA: N8HP) (“CDPR” or the “Corporation”) announces that its Board of Directors has approved the change of the Corporation’s financial year-end from December 31 to March 31 in order to have reporting deadlines occurring during a less busy period for the Corporation and its auditors, thereby facilitating the production of its annual audited financial statements. A Notice of Change in Year-End has been filed by the Corporation on SEDAR+ pursuant to Regulation 51-102 respecting Continuous Disclosure Obligations (“R51-102”). The Corporation also reports that it has appointed Davidson and Company LLP, Chartered Professional Accountants (“Davidson”), as auditors of the Corporation for the current financial year. The appointment follows...